Gilead's Sovaldi gets Chinese approval

By Chris Lieu | Sep 25, 2017 | 9:54 PM GMT

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older.

Gilead said the nucleotide analog HCV NS5B polymerase inhibitor

Read the full 375 word article

How to gain access

Continue reading with a
two-week free trial.